The consequences of a slow or fast metabolism
Benefits of pharmacogenetics in choosing a treatment
Various avenues to explore through pharmacogenetics
For professional support, we’re here for you.
Michel Cameron, PhD
Associate Director, Pharmacogenomics Medical Science LiaisonLinkedIn
Seeking to make the science of genetics accessible for everyone, in 2014 Michel Cameron co-founded BiogeniQ, a company specialized in genetics, where he directed the design and development of pharmacogenomics tests. Today this company is owned by Biron. Michel Cameron holds a Ph.D. in pharmacology from the Université de Montréal and completed postdoctoral studies in pharmacogenomics at the Montreal Heart Institute’s Pharmacogenomics Centre.